ARS Pharmaceuticals, Inc. (SPRY) Operating Margin
- Operating margin · 12 months: Value -184.96%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -184.96% | Operating income / revenue. Period ending 2026-06-30. $-216.27M ÷ $116.93M × 100 ≈ -184.96% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -216.27M USD | Operating Income (Loss) |
| Revenue | 116.93M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 15.23M USD | Research and Development Expense |
| Selling, general and administration | 284.49M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-216.27M | $116.93M | (m) | $15.23M | $284.49M | -184.96% |
| 2026-03-31 | $-202.42M | $98.99M | (m) | $14.56M | $261.22M | -204.49% |
| 2025-12-31 | $-179.45M | $84.28M | (m) | $13.18M | $230.12M | -212.92% |
| 2025-09-30 | $-90.79M | $142.77M | (m) | $12.77M | $205.66M | -63.59% |
| 2025-06-30 | $-59.34M | $112.34M | (m) | $14.44M | $150.19M | -52.82% |
| 2025-03-31 | $-27.07M | $97.12M | (m) | $17.30M | $104.82M | -27.87% |
| 2024-12-31 | $-3.08M | $89.15M | (m) | $19.58M | $71.67M | -3.46% |
| 2024-09-30 | $-60.51M | $2.57M | (m) | $19.96M | $-3.34M | -2356.15% |
| 2024-06-30 | $-56.74M | $500.00K | (m) | $18.54M | $630.00K | -11347.20% |
| 2024-03-31 | $-62.00M | $10.00K | (m) | $18.95M | $696.00K | -619990.00% |
| 2023-12-31 | $-67.52M | $30.00K | (m) | $20.27M | $940.00K | -225066.67% |
| 2023-09-30 | $-72.74M | $30.00K | (m) | $21.57M | (m) | -242456.67% |
| 2023-06-30 | $-61.39M | $219.00K | (m) | $22.46M | (m) | -28031.51% |
| 2023-03-31 | $-47.13M | $673.00K | (m) | $19.50M | (m) | -7002.97% |
| 2022-12-31 | $-35.52M | $1.32M | (m) | $18.38M | (m) | -2698.78% |
| 2022-09-30 | $-86.94M | (m) | (m) | $53.38M | (m) | (m) |
| 2022-06-30 | $-90.68M | (m) | (m) | $60.66M | (m) | (m) |
| 2022-03-31 | $-95.40M | (m) | (m) | $66.16M | (m) | (m) |
| 2021-12-31 | $-89.58M | (m) | (m) | $61.50M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-32.92M | (m) | (m) | $24.58M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |